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Objectives: Sacral neuromodulation is Food and Drug Administration approved for many types of voiding dysfunction. Goals of
treatment often include cessation of anticholinergic therapy. With the goal of understanding the impact of sacral neuromodula-
tion on anticholinergic use, we analyzed patterns of care using a national claims-based dataset.
Materials and Methods: The Ingenix (i3) data base contains insurance claims, including utilization and cost data, for 75 large
employers. De-identiﬁed patients who underwent sacral neuromodulation between 2002 and 2007 were identiﬁed by the unique
current procedural terminology-4 procedure code for pulse generator implantation, code 64590. The number and costs of
anticholinergic prescriptions were compared before and after treatment.
Results: There were 266 percutaneous and 794 two-staged procedures performed from 2002 to 2007 in the i3 dataset. A total of
484 pulse generator implantations were performed, representing 46% of the test procedures. During the year prior to pulse
generator placement, each patient purchased an average of 2.1 prescriptions for an anticholinergic agent (SD 3.5). During the year
after neuromodulation, each patient purchased an average of 1.0 prescription (SD 2.3, p < 0.0001 by t-test). Prescription charges
were $241.31 per patient before and $103.52 after neuromodulation, a statistically signiﬁcant cost diﬀerence (p < 0.0001 by t-test).
During the year before the procedure, 50% of patients ﬁlled anticholinergic prescriptions. This decreased to 23% after the
procedure (p < 0.0001 by chi-square test).
Conclusions Sacral neuromodulation was associated with a signiﬁcant decrease in the use of anticholinergic medication. Cost-
eﬀectiveness analyses that take into account patient quality-adjusted life years are needed to determine the true cost-beneﬁt ratio
of sacral neuromodulation.
Keywords: Claims data, cost, Ingenix (i3), overactive bladder
Conﬂict of Interest: All authors have no conﬂict of interest.
INTRODUCTION
Sacral neuromodulation is Food and Drug Administration
approved for many types of voiding dysfunction refractory to
medical therapy. A systematic review by Siddiqui et al. demon-
strated good eﬃcacy in the treatment of refractory overactive
bladder (OAB), with acceptable surgical revision rates (1). In the case
of OAB symptoms, goals of treatment include the improvement in
urinary frequency, urgency, and urge incontinence. For some
patients, particularly those who do not tolerate anticholinergic
agents, a goal of sacral neuromodulation is cessation or reduction of
anticholinergic use. In some instances, anticholinergic medication is
still required after sacral neuromodulation, with the combination
yielding better results than one treatment alone. However, the
extent to which successful neuromodulation results in a cessation is
unknown or whether there is a decrease in use of anticholinergic
medication.
Sacral neuromodulation is a costly therapy initially, with the
implantation of the lead and pulse generator totaling $15,000 to
$22,000 (2,3). However, the high initial cost of sacral neuromodula-
tion may be oﬀset by long-term eﬃcacy and cost savings over time.
A decrease or cessation of the use of anticholinergic medication
after a successful Interstim (Medtronic, Minneapolis, MN, USA)
implantationmay contribute to such a cost savings.With the goal of
understanding the ﬁnancial and clinical impact of sacral neuro-
modulation on anticholinergic use, we analyzed patterns of care
using a national claims-based dataset.
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MATERIALS AND METHODS
The Ingenix (i3) database contains insurance claims for 75 large
employers, covering over 30million lives. Unlike many claims-based
datasets, the i3 dataset has both utilization and cost data, including
medication charges (4).Thisworkwasa secondary analysis of a larger
project that sought to measure the success of sacral neuromodula-
tion using two national datasets, Ingenix and Medicare (5). The i3
database was used to determine demographic, diagnosis, and cost
information on de-identiﬁed patients who underwent sacral neuro-
modulationbetween thesecondquarterof2002and theﬁrstquarter
of 2007. Each patient was linked by a unique patient identiﬁcation
number. Patients were initially identiﬁed by the unique current pro-
cedural terminology (CPT)-4 procedure code for a test stimulation in
the sacral foramen either percutaneously (64561) or with an incision
(64581), as previously described (5). International Classiﬁcation of
Diseases, NinthRevisiondiagnosis codes identiﬁed the indication for
the procedure(s), which included codes for frequency, urgency, noc-
turia, urge incontinence (OAB symptoms), neurogenic voiding dys-
function, interstitial cystitis, and incomplete bladder emptying or
nonobstructive urinary retention. All other urologic diagnoses asso-
ciated with a procedure that did not ﬁt into one of the previously
mentioned categories were grouped into the “other” category. Any
person who had no urologic diagnosis whatsoever associated with
theirprocedurewasexcluded, as these likely representedother types
of neuromodulating devices.
Successful percutaneous test stimulation was deﬁned as a percu-
taneous test followed by a simultaneous permanent lead and pulse
generator implant. A successful two-stage test was deﬁned as a
surgical lead placement followed by a pulse generator placement at
a later date. Those who proceeded to pulse generator implantation,
CPT-4 code 64590, were considered a treatment success, and were
therefore included in this analysis. Statistical analysis was performed
using Statistical Analysis Software (SAS Institute, Inc., Cary, NC, USA).
The average number of anticholinergic prescriptions and the
charges for prescriptions were calculated and compared before and
after pulse generator implantation. p Values of 0.05 were consid-
ered statistically signiﬁcant.
RESULTS
There were 266 percutaneous and 794 two-staged procedures
performed from 2002 to 2007 in the Ingenix dataset. As previously
described, a total of 484 pulse generator implantations were per-
formed, representing 46% of the test procedures (5). Percutaneous
procedures were successful in 24.1% of cases, compared with 50.9%
following staged procedures (p < 0.0001). During the year prior to
undergoing sacral neuromodulation, each patient purchased an
average of 2.1 prescriptions for an anticholinergic agent (SD 3.5,
Table 1). During the year after neuromodulation, each patient pur-
chased an average of 1.0 prescription (SD 2.3, p < 0.0001 by t-test).
The largest drop in anticholinergic use was seen among patients
with OAB wet (from 7492 prescriptions to 5632), followed by OAB
dry (from 7151 to 5898, data not shown).
Anticholinergic prescription charges were $241.31 per patient
before and $103.52 after neuromodulation, a statistically signiﬁcant
cost diﬀerence (p < 0.0001 by t-test, Table 1). During the year before
the procedure, 50% of patients ﬁlled anticholinergic prescriptions.
This decreased to 23% after the procedure (p < 0.0001 by chi-square
test). Of the 112 patients who were prescribed an anticholinergic
agent after neuromodulation, 40% had their last prescription less
than 180 days after the implant, possibly indicating a gradual reduc-
tion in anticholinergic use over time.
DISCUSSION
We found that anticholinergic use decreased by over 50% after
Interstim implantation. This may indicate signiﬁcant eﬃcacy of the
device such that anticholinergic medication use was either
decreased or stopped altogether. Given that many patients who
begin anticholinergics are given samples (and do not necessarily ﬁll
prescriptions), we suspect that anticholinergic use in the year before
sacral neuromodulation was actually higher than 50%. Should this
be the case, the reduction in anticholinergic use may actually be
greater than what we found. Although sacral neuromodulation is
usually recommended to patients whose symptoms are refractory
to medical therapy, some patients proceed to Interstim because
they either cannot tolerate anticholinerigcs or prefer not to take
medication on a regular basis.What cannot be determined from this
dataset is the reason for cessation of anticholinergic use. It is pos-
sible that some patients stopped medication use for reasons other
than success of the pulse generator, such as side-eﬀects or lack of
eﬃcacy of medication. Also, cessation could have occurred before
the actual device was implanted. In addition, this population
included a small percentage of patients (9.5%) who underwent
Interstim therapy for urinary retention, and anticholinergic use
would only be used in those patients with incomplete bladder emp-
tying and concomitant irritative symptoms (vs. complete retention)
(5). Regardless, our ﬁndings shed light on the relationship between
sacral neuromodulation and anticholinergic use among all patients
undergoing Interstim.
The decrease in use of anticholinergics in the year following pulse
generator implantation resulted in a cost savings of $137.79 in pre-
scription charges. This is consistent with the ﬁndings of Aboseif
et al., who found that drug expenditures decreased by 30% after
Interstim in 65 patients, from $693 to $483 per patient (p < 0.02).
They also found a mean decrease in oﬃce visits of 2.2 visits in the
year after implant, which corresponds to a 73% reduction in oﬃce
visit expenses, from $994 to $265 per patient (6). From a ﬁnancial
perspective, this savings in prescription charges appears quite small
compared with the initial cost of the Interstim pulse generator.
Though sacral neuromodulation is costly initially, and has been
shown to be more costly than repeated injections of botulinum
toxin after two years (7), sacral neuromodulation becomes more
Table 1. Comparison of Prescription Usage and Cost Before and After Sacral Neuromodulation.
Year before neuromodulation Year after neuromodulation p Value
Average no. prescriptions purchased 2.1  3.5 1.0  2.3 <0.0001
Anticholinergic prescription charges (per patient) $241.31 $103.52 <0.0001
% patients ﬁlling anticholinergic prescription 50% 23% <0.0001
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cost-eﬀective than other modalities after ﬁve years (8). In addition,
long-term cessation of anticholinergic medication, with its associ-
ated side-eﬀects of dry mouth, dry eyes, and constipation, can sig-
niﬁcantly improve one’s quality of life, providingmore than a simple
ﬁnancial savings. Though patients in the i3 database continued to
ﬁll an average of one prescription in the year after Interstim, a large
minority of these occurred in the ﬁrst six months after the implant,
suggesting that medication use was stopped over time. What
cannot be measured in claims data is the impact on health-related
quality of life that these patients experienced as a result of Interstim.
CONCLUSIONS
Sacral neuromodulation was associated with a signiﬁcant
decrease in use of anticholinergic medication, as evidenced by
fewer expenditures on anticholinergic agents and 50% fewer pre-
scriptions ﬁlled. In order to determine the true cost-beneﬁt ratio of
sacral neuromodulation, cost-eﬀectiveness analyses that take into
account patient quality-adjusted life years and costs over time are
needed.
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